In March 2012 Otsuka's three-year Phase I-IIIb strategic collaboration with Covance will be up for renewal.
Amgen's tox capacity tie-up with Covance
June 2013 will see the end of a siz-year toxicology deal between Amgen and Covance. Amgen got guarenteed tox capacity in a deal that added $150m to Covance's backlog.
B-MS' two partners deal
In June 2013 three-year development support deals Bristol-Myers Squibb struck with Icon and Parexel will be due for renewal.
Merck's vaccine testing deal with PPD
In January 2014 the five-year deal that accompanied the transfer of Merck's vaccine testing lab to PPD is due to end.
Merck & Covance's genomic services agreement
Merck was busy in 2009, following up the PPD deal with a five-year agreement with Covance. The genomic services deal, worth $145m, is due for renewal in July 2014.
Pfizer's partnership with Parexel & Icon
Pfizer looked to consolidate its vendor list in May 2011 and selected Icon and Parexel as its providers. In May 2016 the deal will be up for renewal.
Eli Lilly's tox deal with Covance
In August 2008 Eli Lilly gave the strategic partnership concept a shot-in-the-arm by inking a 10-year deal with Covance. Lilly transferred a IN site to Covance as part of the $1.6bn deal that is up for renewal in August 2018.
Sanofi's wide-reaching Covance deal
Sanofi leapt into the strategic deal game in October 2010 with a 10-year, $2.2bn partnership with Covance. In October 2020 the deal will be up for renewal.